Redeye presents its preview of Sedana Medical’s Q2 2024 report, due on July 23.
Refine Group AB ("Refine", "Koncernen" eller "Bolaget") meddelade den 28 juni år 2024 att dotterbola...
Profitability below expectations Duell’s Q3 net sales came in at EUR 37.
Redeye initiates coverage on CoinShares (CS), a leading crypto asset manager holding a European mark...
Railcare säkrar tillgång till framtidssäkrade lok genom innovativ affär.
Luxbright har levererat en första leverans av ett kundspecifikt röntgenrör till Fisica Inc.
Redeye updates its estimates ahead of the Q2 report following today’s announced 5G order.
Cereno Scientific has released updates on its two most advanced clinical programmes.
Redeye offers a preview of Doro's Q2 results set to be released on July 17th.
Redeye offers a preview of Advenica's Q2 results set to be released on July 19th.
Redeye provides an update as we resume our coverage after CLS’ rights issue.
Ahead of Cibus' Q2 2024 report, we incorporate the acquisition of six properties, announced in late ...
Our earnings bridge: We expect Q2 Paper EBIT of PLN 38m, down from PLN 94m in Q1'24.
Q2 likely similar to Q1 Q2 seems to have developed in a similar way to Q1, with the trend of longer ...
What to expect in Q2'24 We expect sales of SEK 266m for Q2'24, implying a y-o-y decline of -11%, alo...
Redeye shares its preview of BONESUPPORT’s Q2 2024e results, due 11 July.
Duell publishes its business review for Q3 (March-May) on Wednesday 3rd of July.
Redeye briefly comments on Navigo announcing several leadership changes.
Last week Railcare announced a deal that will secure the supply of locomotives for some of its impor...
Redeye comments on the continued expansion into California with a new collaboration with United Heal...
